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A B S T R A C T
Purpose
Three cycles of bleomycin, etoposide, and cisplatin (BEP 3 3) or four cycles of etoposide and
cisplatin (EP3 4) are first-line chemotherapy regimens for men with International Germ Cell Cancer
Collaborative Group (IGCCCG) good-risk germ cell tumors (GCTs).We determinedwhether inclusion
of bleomycin affected pulmonary and operative morbidity after postchemotherapy retroperitoneal
lymph node dissection (PC-RPLND).
Patients and Methods
We queried our database to identify IGCCCG good-risk patients who received BEP 3 3 or EP 3 4
induction chemotherapy before PC-RPLND from 2006 to 2016. Patients who received combination
regimens were excluded. The primary outcomes of interest were pulmonary morbidity (prolonged
intubation, reintubation, supplemental oxygen use, intensive care unit stay) and operative morbidity
(operative time, length of stay, concomitant procedures, estimated blood loss).
Results
We analyzed 234 patients (191 BEP3 3 v 43 EP3 4). All patients were extubated immediately after
the operation. Nonewere reintubated or discharged on oxygen. Two patients in each cohort required
an intensive care unit stay for nonpulmonary reasons. Patients treatedwith BEP required shorter use
of supplemental oxygen (0.99 v 1.63 days; P = .005). No significant differences were found in
preoperative mass size (P = .42) or concomitant surgeries (P = .58). Operative time was significantly
shorter (131 v 170minutes; P, .01), and estimated blood losswas considerably less (194 v 226mL;
P, .01) in patients treated with BEP. Length of stay was shorter in patients treated with BEP (3.3 v
3.9 days; P , .01).
Conclusion
In a modern surgical cohort, the inclusion of bleomycin does not seem to influence pulmonary
morbidity, operative difficulty, or nonpulmonary postoperative complications after PC-RPLND in
men with IGCCCG good-risk GST.
J Clin Oncol 36:2950-2954. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The discovery of the unique sensitivity of non-
seminomatous germ cell tumors (GCTs) to
cisplatin-based combination chemotherapy regi-
mens revolutionized the treatment and survival of
men with testicular cancer.1 Initial regimens of
cisplatin, vinblastine, and bleomycin yielded
complete response rates of 74% and long-term
survival rates of 70%, but treatment toxicity was
high.2-4 As a result, the goals of treatment shifted
to identify induction chemotherapy regimens that
limited treatment-related toxicities while main-
taining excellent cure rates, especially in menwith
good-risk disease.
Numerous randomized controlled trials in-
vestigated various induction regimens.4-11 Cur-
rently, the National Comprehensive Cancer
Network endorses either three cycles of bleo-
mycin, etoposide, and cisplatin (BEP3 3) or four
cycles of etoposide and cisplatin (EP 3 4) as
acceptable induction chemotherapy regimens for
patients with International Germ Cell Cancer
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Collaborative Group (IGCCCG) good-risk disease.12 However, the
debate continues about which chemotherapy regimen is best for
men with good-risk disease.
A recent publication from our group evaluated the risk of
postoperative complications in patients who undergo resection of
primary mediastinal GCTs after chemotherapy.13 Complications
were higher in men who received BEP compared with etoposide,
ifosfamide, and cisplatin, likely because of extensive chest surgery;
thus, these findings prompted us to determine whether the same
was true with abdominal surgery. Therefore, in the current study,
we investigated the incidence and significance of bleomycin-related
pulmonary and operative morbidity in men with IGCCCG good-
risk nonseminomatous GCTs who underwent postchemotherapy
retroperitoneal lymph node dissection (PC-RPLND). We hy-
pothesized that the inclusion of bleomycin in induction regimens
would not increase pulmonary or operative morbidity, which may
alleviate some of the toxicity concerns of this regimen.
PATIENTS AND METHODS
Study Cohort
Our prospectively maintained Indiana University Testis Database was
queried to identify IGCCCG good-risk patients who underwent PC-
RPLND between 2006 and 2016 and received either BEP 3 3 or EP 3 4.
Inclusion criteria were men diagnosed with nonseminomatous GCTs of
the testis, good-risk disease as defined by IGCCCG criteria, receipt of either
BEP 3 3 or EP 3 4 as induction chemotherapy, residual retroperitoneal
mass . 1 cm, and normal preoperative serum tumor markers. We began
the study period in 2006 because intraoperative anesthesia records had
become readily retrievable. A total of 234 patients met criteria for eval-
uation; 191 received BEP 3 3, and 43 received EP 3 4.
Anesthetic Management
The anesthetic management is similar at our institution for all patients
who undergo RPLND for residual disease regardless of induction chemo-
therapy regimen. Brief episodes of a high fraction of inspired oxygen (FIO2) are
used during induction of and emergence from anesthesia. The FIO2 is sub-
stantially decreased for the remainder of the operation. Typically, the FIO2 is
kept between 30% and 40% for the majority of the operation. Intraoperative
resuscitation is minimized and not driven by intraoperative urine output.
Additional fluid is not given to compensate for nothing by mouth status.
Patients typically are given 4 mL/kg/h lactated ringers and 2 mL/kg/h albumin
for the first 2 hours of the operation. Volume and vital status are then
reassessed at that point to dictate additional resuscitation. Blood transfusions
are administered only if clinically indicated. After the completion of the
operation and before emergence, patients typically are placed in lateral
decubitus position and administered a single shot of intrathecal narcotic.
Independent Variables and Outcome
The primary outcomes of the study were pulmonary and operative
morbidity. Pulmonary outcomes included prolonged intubation (defined
as . 1 day), need for reintubation, intensive care unit need and duration,
and supplemental oxygen duration. Operative outcomes included oper-
ative time, length of stay, estimated blood loss, and performance of
concomitant procedures.
Statistical Analysis
Baseline characteristics of the BEP 3 3 and EP 3 4 groups were
compared using t tests for differences in means of normally distributed
continuous variables and the Mann-Whitney U test for nonnormally
distributed continuous variables. Pearson x2 and Fisher’s exact tests were
used for categorical variables. All statistical tests were two sided with
significance set at P , .05. Stata/IC 12.1 statistical software (StataCorp,
College Station, TX) was used to conduct the analysis.
RESULTS
Table 1 lists the baseline demographic and clinical characteristics of
the study cohort stratified on the basis of induction chemotherapy
regimen. The group characteristics were similar. Men who received
BEP 3 3 were younger than those who received EP 3 4 (27 v 31
years; P , .01). Indications for the use of EP 3 4 were referring
oncologist preference (28 [65.1%]), patient age older than 50 years
(seven [16.2%]), pulmonary insufficiency at baseline (two [4.7%]),
and extensive pulmonary metastatic disease at presentation (six
[14%]). None of these patients were treated or seen before the start
of chemotherapy at our institution. Clinical stage at presentation
was similar between the groups (P = .12). No significant differences
were seen in preoperative mass size between groups (P = .42).
Pulmonary morbidity after PC-RPLND was low in all patients
regardless of induction chemotherapy regimen. All patients were
successfully extubated at the conclusion of the operation, and no
patient in either group required postoperative reintubation. Only
four patients required postoperative monitoring in the intensive
care unit, all for nonpulmonary-related issues (two of whom re-
ceived BEP 3 3 and two of whom received EP 3 4). The duration
of supplemental oxygen use was shorter in patients treated with
BEP3 3 (0.98 v 1.61 days; P, .01). Pulmonary-related outcomes
on the basis of chemotherapy type are listed in Table 2. These
outcomes occurred despite concomitant thoracic procedures being
more common in patients who underwent BEP3 3 versus EP3 4
(Table 3). Briefly, seven patients who underwent BEP3 3 required
thoracic procedures. Two patients underwent video-assisted
Table 1. Preoperative Demographics and Clinical Data on the Basis of
Induction Chemotherapy Regimen
Characteristic
BEP Cohort,
No. (%)
EP Cohort,
No. (%) P
No. of patients 191 43
Age, years (IQR) 27 (22-32) 31 (25-41) , .01
Orchiectomy pathology .33
NSGCT 176 (92) 37 (79)
Seminoma* 2 (1) 0 (0)
Other† 9 (5) 4 (9)
Missing 4 (2) 2 (5)
Clinical stage at presentation .12
I 65 (34) 7 (16)
II 81 (42) 23 (54)
III 28 (15) 9 (21)
Missing 17 (9) 4 (9)
Preoperative mass size, cm .42
, 2 27 (19) 8 (21)
2-5 80 (57) 18 (46)
. 5 34 (24) 13 (33)
Missing 50 4
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and
cisplatin; IQR, interquartile range; NSGCT, nonseminomatous germ cell tumor.
*Both patients with seminoma had elevated alpha-fetoprotein at presentation.
†Other consists of scar, intratubular germ cell neoplasia, and fibrosis.
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thoracotomies for small-volume residual parenchymal lesions. Five
patients underwent open thoracotomy during which two required
only wedge resections (eight lesions total), and three required
a mediastinal dissection and/or lobectomy. The two patients who
received EP 3 4 and underwent concomitant thoracic procedures
had higher-volume disease in the chest at the time of diagnosis.
One patient required a sternotomy, thymectomy, anterior superior
mediastinal dissection, and removal of a large paratracheal residual
mass. The other patient required a thoracotomy, extensive me-
diastinal dissection, and a pulmonary wedge resection.
Operative morbidity after PC-RPLND was similarly low in all
patients, although a few differences were seen between groups.
Operative time was approximately 40 minutes shorter for those
who received BEP 3 3 (131 v 170 minutes; P , .01). Estimated
blood loss also was lower in the BEP 3 3 cohort (194 v 226 mL;
P , .01) as was length of stay (3.3 v 3.9 days; P , .01). Only five
patients required a blood transfusion during the operation or the
postoperative stay (three BEP3 3 v two EP3 4). These differences
in operative outcomes between the two groups were not a result
of differences in preoperative mass size (P = .42) or concomitant
procedures (8.9% v 11.6%; P = .58). Operative outcomes on the
basis of chemotherapy type are listed in Table 3.
DISCUSSION
The current study demonstrates that pulmonary toxicity and operative
morbidity at the time of PC-RPLND in men with IGCCCG good-risk
nonseminomatous GCTs was exceedingly low in those who received
bleomycin as a component of the induction chemotherapy regimen.
No patient required prolonged intubation or reintubation. All patients,
regardless of regimen, required supplemental oxygen for only 1
postoperative day. In addition, estimated blood loss and operative
times statistically favored BEP3 3, but the clinical significance of this is
uncertain. Finally, the proportion of patients who required additional
procedures at the time of PC-RPLND were similar between groups.
The concern for bleomycin-induced pulmonary toxicity
(BPT) is one of the most common reasons why EP3 4 is preferred
over BEP 3 3 in men with IGCCCG good-risk metastatic GCTs.
However, studies that evaluated the risk of BPT in this setting
do not support such concerns. A prospective cohort study of 835
men treated with bleomycin-containing chemotherapy regimens
assessed the incidence and risk factors of BPT. Overall, only 6.8%
of patients had BPT, and the risk of death directly attributable to
BPT was 1%. Factors that independently predict BPT were renal
function (glomerular filtration rate, , 80 mL/min), age (. 40
years), and cumulative dose of bleomycin (. 300 IU). Rates of BPT
using BEP 3 3 (30 IU weekly 3 9 = 270 IU) for good-risk disease
were much lower than rates of BPT for men with intermediate- to
high-risk disease administered BEP3 4 (30 IU weekly3 12 weeks
= 360 IU).14 These results were corroborated by a prospective,
unselected (ie, containing men with all IGCCCG risk groups)
cohort study. Acute and chronic pulmonary complications in 565
men treated with BEP for metastatic GCTs were minimal and
predominantly limited to high-risk individuals (IGCCCG poor
risk, pulmonary surgery, and pulmonary embolus before or during
treatment).15 Finally, in a prospective randomized trial that
compared the efficacy and toxicity of BEP 3 3 versus EP 3 4 in
good-risk nonseminomatous GCTs, pulmonary toxicity occurred
in 12 patients who received BEP 3 3 and eight patients who re-
ceived EP 3 4 (P = .38).16
A meta-analysis of randomized controlled trials that evaluated
the incidence of BPT in men with metastatic GCTs published
contrasting results. The probability of all-grade and high-grade
pulmonary toxicity was higher in men treated with bleomycin than
in those who were not (12% v 2% and 6% v 1%, respectively). On
multivariable analysis, bleomycin increased the odds of all-grade
(but not high-grade) pulmonary toxicity.17 This study included
men treated with various chemotherapy dosages and regimens and
IGCCCG risk categories. When specifically evaluating men with
IGCCCG good-risk disease treated with 270 IU bleomycin, the
event rate of all-grade and high-grade pulmonary toxicity is ex-
ceeding low, with some large trials reporting a 0% incidence of
BPT.7,17 Thus, when evaluating the totality of the existing evidence,
BPT is extremely rare in patients treated with BEP3 3. The current
study in a surgical cohort supports this statement and adds that
peri-operative pulmonary complications are minimal in men who
require a PC-RPLND for residual disease, regardless of induction
chemotherapy regimen. In fact, no patient in either chemotherapy
group experienced a significant pulmonary complication during
the peri-operative or immediate postoperative period. This con-
trasts our group’s previous findings that bleomycin-containing
chemotherapy compared with etoposide, ifosfamide, and cisplatin
greatly increases postoperative pulmonary complications in men
Table 2. PulmonaryMorbidity After Postchemotherapy Retroperitoneal Lymph
Node Dissection on the Basis of Induction Chemotherapy Regimen
Variable
BEP Cohort
(n = 191)
EP Cohort
(n = 43) P
Intubation duration, days 0 0 NA
No. needing reintubation 0 0 NA
No. needing intensive care unit
stay (%)
2 (1) 2 (5) .054
Mean duration of supplemental
oxygen, days
0.99 1.63 , .01
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and
cisplatin; NA, not applicable.
Table 3. Operative Morbidity After Postchemotherapy Retroperitoneal Lymph
Node Dissection on the Basis of Induction Chemotherapy Regimen
Variable
BEP Cohort
(n = 191)
EP Cohort
(n = 43) P
Operative time, minutes 131 170 , .01
Estimated blood loss, mL 194 243 .01
Length of stay, days 3.3 3.9 , .01
No. of additional procedures
at time of RPLND (%)
17 (8.9) 5 (11.6) .58
Nephrectomy 1 1
Thoracic procedure 7 2
Vascular procedure 3 0
Bowel resection 2 2
Orchiectomy 1 0
Appendectomy/Meckel’s
diverticulectomy
2 0
Ureteral resection 1 0
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and
cisplatin; RPLND, retroperitoneal lymph node dissection.
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who require extensive chest surgery for primary mediastinal GCT.13
Thus, selection of induction chemotherapy regimen in men with
IGCCCG good-risk GCTs with minimal pulmonary disease should
be made independently of the concern for pulmonary toxicity,
except in men with documented risk factors (age, poor renal
function, preexisting pulmonary insufficiency).
Complication rates after PC-RPLND are substantially higher
than after primary RPLND. A retrospective study that evaluated
1,081 men who underwent PC-RPLND or primary RPLND re-
ported major complication rates of 18% and 8%, respectively.18,19
Obvious differences in the clinical scenario explain the differences
in complication rates, including stage of disease, size of lymph
node mass, and presence of postchemotherapy desmoplastic re-
action. Some have hypothesized that bleomycin-containing che-
motherapy regimens increase surgical morbidity.20 The current
study does not substantiate such claims. Operative morbidity was
low in all patients in the current study, regardless of type of in-
duction chemotherapy, which suggests that chemotherapy regimen,
especially those that contain bleomycin, does not influence operative
morbidity and does not have an effect on the surgical dissection.
The current study should be considered in the context of
certain limitations. First, the inherit weakness of a retrospective
analysis of a prospectively maintained database are well docu-
mented. However, no previous clinical trial or prospective cohort
to our knowledge has reported pulmonary and operativemorbidity
stratified by chemotherapy regimen in men with IGCCCG good-
risk disease. Second, our institutional preference of using BEP
induction chemotherapy in men younger than 50 years old without
significant pulmonary comorbidities is well known, which may
represent inherent selection bias. However, as a tertiary referral
center, patients often present with residual retroperitoneal disease
after the completion of chemotherapy; therefore, the induction
chemotherapy regimen often is at the discretion of the referring
oncologist. This is highlighted by the fact that only 30 patients
(12.8%) in the current cohort were treated or seen at our in-
stitution before the start of chemotherapy. Third, pulmonary
morbidity was not assessed using the results of pulmonary function
tests (PFTs). We instead opted to evaluate this end point by using
clinically important variables, such as need for prolonged in-
tubation and supplemental oxygen use. Of note, we routinely do
not perform PFTs for good-risk patients who receive BEP 3 3
unless they have an abnormal history or physical examination. The
only patients inwhomwe occasionally perform PFTs are those with
intermediate- or poor-risk disease. In these patients, PFTs
sometimes are done at baseline and just before the fourth cycle to
ensure that the 10th, 11th, and 12th doses of bleomycin can be
administered safely. Fourth, because a majority of patients received
chemotherapy at referring centers, dosing, dose reductions, and
treatment delays were not reliably captured. However, we have
previously demonstrated that good-risk patients who were treated
with BEP 3 3 at Indiana University versus an outside referral
center and underwent PC-RPLND at our center had similar
survival and histologic outcomes.21 This likely underscores the
importance of surgical management at experienced referral centers
for men with bulky and aggressive disease and of appropriate
anesthetic and postoperative treatment of these individuals (lower
FIO2, removal of supplemental oxygen quickly, etc).
These limitations notwithstanding, we believe that the data
presented in this study add sufficient and compelling evidence
about the safety of bleomycin in chemotherapy regimens for men
with IGCCCG good-risk disease who require PC-RPLND. Pul-
monary morbidity was low regardless of induction chemotherapy
approach; therefore, the perceived pulmonary toxicity of bleo-
mycin in this patient cohort is unsubstantiated. Although the
improved operative outcomes may be linked to residual con-
founding and poorly explained clinically, it is safe to assume that
operative difficulty and postoperative complications are not as-
sociated with chemotherapy regimen and are linked more strongly
to surgeon experience, location of treatment, extent of disease, and
preexisting medical comorbidities.
In conclusion, we found that pulmonary morbidity is not
increased inmenwho receive bleomycin-containing chemotherapy
for IGCCCG good-risk testicular cancer. Operative outcomes were
similar, if not statistically improved, in the cohort that received
BEP. This phenomenon is hard to explain yet justifies that the
inclusion of bleomycin likely does not influence operative diffi-
culty or nonpulmonary postoperative complications. Given these
findings, oncologists should consider the indications of using EP
regimens in this patient population and potentially limiting the use
in older men with preexisting pulmonary disease.
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